The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Trend alert! Split dosing, stretch dosing, skip dosing, microdosing Ozempic… People are finding creative ways to use ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Beneil Dariush returned to action for the first time since 2023, and picked up a much-needed win over Renato Moicano.

2025 WWE Night of Champions results, grades, winners, recap: John Cena retains title in chaotic main event Cena defeated CM Punk despite appearances from Seth Rollins, Bron Breakker, Bronson Reed ...

In this weekly Plain Facts compilation, we present to you data-based insights, with easy-to-read charts, to help you delve deeper into the stories reported by Mint in the week gone by.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with weight-loss drugmaker Novo Nordisk abruptly ended.